Overall, these evidences suggest that NGF-based therapy could improve neurological outcomes that are related to dysfunctions of the central cholinergic system, both in neurodegenerative diseases (Mufson et al., 2019) and after TBI (Shin and Dixon, 2015), normalizing APP and tau metabolism in TrkA-expressing cells. This evidence concerns the gene APP and neurodegenerative disease.